Drug
Stx 241
Stx 241: highest development phase Phase 1/2, developed by Pierre Fabre. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Pierre Fabre
Trials
| Drug | Phase | Indication |
|---|---|---|
| STX-241 NCT06567015 | Phase 1/2 | Non-small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow Stx 241 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.